Tag Archives: Could

AMAG wins FDA nod for Vyleesi. Could it be the ‘female Viagra’ that Addyi never was?

Valeant, now Bausch Health, paid $ 1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status Valeant once touted, a rival has arrived. The FDA late Friday approved AMAG Pharmaceuticals’ Vyleesi (bremelanotide) to treat premenopausal women with… Read More »

Public option, increased premium credits could save $12B

Dive Brief: Introducing a public option in the nongroup market and broadening eligibility for Affordable Care Act marketplace premium tax credits could save the federal government $ 12 billion in 2020 and cover an additional 1.2 million people, according to a recent report from the Urban Institute. The public option (or, alternatively, capping provider payment… Read More »

A small electrical zap to the brain could help you retrieve a forgotten memory

A study by UCLA psychologists provides strong evidence that a certain region of the brain plays a critical role in memory recall. The research, published in the Journal of Cognitive Neuroscience, also shows for the first time that using an electrical current to stimulate that region, the left rostrolateral prefrontal cortex, improves people’s ability to… Read More »